{"id":881763,"date":"2025-09-03T17:01:56","date_gmt":"2025-09-03T21:01:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/"},"modified":"2025-09-03T17:01:56","modified_gmt":"2025-09-03T21:01:56","slug":"update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/","title":{"rendered":"UPDATE — vTv Therapeutics to Participate in Upcoming September Investor Conferences"},"content":{"rendered":"
\n

HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) — vTv Therapeutics Inc.\u00a0(Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:<\/p>\n\n\n\n\n\n\n\n\n\n
\n H.C. Wainwright\u00a027th Annual Global Investment Conference<\/strong>
\n \n <\/td>\n<\/tr>\n
Date:<\/td>\nTuesday, September 9, 2025<\/td>\n<\/tr>\n
Format:<\/td>\n1×1 Investor Meetings Only<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Morgan Stanley 23rd Annual Global Healthcare Conference\u00a0<\/strong>\n <\/td>\n<\/tr>\n
Date:<\/td>\nWednesday, September 10, 2025<\/td>\n<\/tr>\n
Format:<\/td>\nFireside Chat Time: 2:35 PM – 3:10 PM EST and 1×1 Investor Meetings<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n About<\/strong>\u00a0vTv<\/strong>\u00a0Therapeutics<\/strong>
vTv Therapeutics\u00a0is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv\u2019s clinical pipeline is led by\u00a0cadisegliatin<\/em>, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at\u00a0vtvtherapeutics.com<\/a>\u00a0or follow the company on\u00a0LinkedIn<\/a>\u00a0or\u00a0X<\/a>.<\/p>\n

\n Investor Contact<\/strong>
\n
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com<\/a><\/p>\n

\n Media Contact<\/strong>
\n
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) — vTv Therapeutics Inc.\u00a0(Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences: H.C. Wainwright\u00a027th Annual Global Investment Conference Date: Tuesday, September 9, 2025 Format: 1×1 Investor Meetings Only \u00a0 \u00a0 Morgan Stanley 23rd Annual Global Healthcare Conference\u00a0 Date: Wednesday, September 10, 2025 Format: Fireside Chat Time: 2:35 PM – 3:10 PM EST and 1×1 Investor Meetings \u00a0 \u00a0 About\u00a0vTv\u00a0TherapeuticsvTv Therapeutics\u00a0is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living … <\/p>\n

Continue reading “UPDATE — vTv Therapeutics to Participate in Upcoming September Investor Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-881763","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nUPDATE - vTv Therapeutics to Participate in Upcoming September Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UPDATE - vTv Therapeutics to Participate in Upcoming September Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) — vTv Therapeutics Inc.\u00a0(Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences: H.C. Wainwright\u00a027th Annual Global Investment Conference Date: Tuesday, September 9, 2025 Format: 1×1 Investor Meetings Only \u00a0 \u00a0 Morgan Stanley 23rd Annual Global Healthcare Conference\u00a0 Date: Wednesday, September 10, 2025 Format: Fireside Chat Time: 2:35 PM – 3:10 PM EST and 1×1 Investor Meetings \u00a0 \u00a0 About\u00a0vTv\u00a0TherapeuticsvTv Therapeutics\u00a0is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living … Continue reading "UPDATE — vTv Therapeutics to Participate in Upcoming September Investor Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-03T21:01:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjk0MiM3MTI5MjM1IzIwMTk3OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"UPDATE — vTv Therapeutics to Participate in Upcoming September Investor Conferences\",\"datePublished\":\"2025-09-03T21:01:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/\"},\"wordCount\":208,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjk0MiM3MTI5MjM1IzIwMTk3OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/\",\"name\":\"UPDATE - vTv Therapeutics to Participate in Upcoming September Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjk0MiM3MTI5MjM1IzIwMTk3OTU=\",\"datePublished\":\"2025-09-03T21:01:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjk0MiM3MTI5MjM1IzIwMTk3OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjk0MiM3MTI5MjM1IzIwMTk3OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UPDATE — vTv Therapeutics to Participate in Upcoming September Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"UPDATE - vTv Therapeutics to Participate in Upcoming September Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"UPDATE - vTv Therapeutics to Participate in Upcoming September Investor Conferences - Market Newsdesk","og_description":"HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) — vTv Therapeutics Inc.\u00a0(Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences: H.C. Wainwright\u00a027th Annual Global Investment Conference Date: Tuesday, September 9, 2025 Format: 1×1 Investor Meetings Only \u00a0 \u00a0 Morgan Stanley 23rd Annual Global Healthcare Conference\u00a0 Date: Wednesday, September 10, 2025 Format: Fireside Chat Time: 2:35 PM – 3:10 PM EST and 1×1 Investor Meetings \u00a0 \u00a0 About\u00a0vTv\u00a0TherapeuticsvTv Therapeutics\u00a0is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living … Continue reading \"UPDATE — vTv Therapeutics to Participate in Upcoming September Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-03T21:01:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjk0MiM3MTI5MjM1IzIwMTk3OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"UPDATE — vTv Therapeutics to Participate in Upcoming September Investor Conferences","datePublished":"2025-09-03T21:01:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/"},"wordCount":208,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjk0MiM3MTI5MjM1IzIwMTk3OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/","name":"UPDATE - vTv Therapeutics to Participate in Upcoming September Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjk0MiM3MTI5MjM1IzIwMTk3OTU=","datePublished":"2025-09-03T21:01:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjk0MiM3MTI5MjM1IzIwMTk3OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjk0MiM3MTI5MjM1IzIwMTk3OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-vtv-therapeutics-to-participate-in-upcoming-september-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"UPDATE — vTv Therapeutics to Participate in Upcoming September Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=881763"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881763\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=881763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=881763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=881763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}